The Effects of Cannabis on Mental Health

Information Sheet for Health Professionals

External Affairs & Policy

Here you will find our mission and objectives, learn about External Affairs & Policy, our team and how we work.

This information sheet is aimed at health professionals and aims to answer 20 Frequently Asked Questions about cannabis. Cannabis and cannabis-based products are becoming more widespread within Ireland. People who use the mental health services, both children and adults are at higher vulnerability to the harms of cannabis use. Health professionals should be familiar with these risks as the media as well as patients are likely to underestimate the harms of cannabis use.

  • Cannabis is the mostly commonly used illegal drug in Ireland
  • Cannabis is easily available in Ireland including high potency versions
  • Cannabis adversely affects mental health
  • Young people who use high potency cannabis regularly are at highest risk of harms
  • Cannabis can be addictive
  • Cannabis and cannabis products are not evidence-based treatments for mental illness
  • Cannabis use is associated with many social and educational problems

View this information sheet as a PDF here.

Cannabis is a psychoactive drug derived from a genus of plants of the same name.  Cannabis is most commonly available in Ireland in the form of herbal cannabis (“weed”, “grass”) or cannabis resin (“hashish” or “hash”). There are also high potency cannabis extracts, such as oil, shatter or wax. The majority of cannabis use in Ireland is via smoking1. Cannabis products can also be inhaled via vaping or “dabbing” or ingested orally (“edibles”).

Cannabis is the most widely used illegal drug in Ireland. The National Advisory Committee on Drugs and Alcohol (NACDA)¹ conducted a general population study in 2014/2015 and found 1 in 4 of respondents had used cannabis at least once in their lifetime with 6.5% of respondents reporting cannabis use within the last month. Cannabis use is highest in young adults, and regular use is more common among males than females. Results from the European School Survey Project on Alcohol and Other Drugs (ESPAD)² study in 2019 showed that 9% of Irish Transition Year Students (aged 15-16) in Ireland had used cannabis in the past month.

Cannabis contains over one hundred cannabinoids, the two most researched are the phytocannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabinoids exert their effects primarily by interacting with the endocannabinoid system, which comprises endogenous ligands such as N-arachidonoylethanolamide and 2-arachidonoylglycerol. There are two specific receptors – cannabinoid receptor type-1 (CB1) and cannabinoid receptor type-2 (CB2). A large number of synthetic cannabinoids also exist designed to imitate the actions of THC with a higher risk of adverse effects³.

The two cannabinoids act quite differently with different affinity for the different cannabinoid receptors. THC is the psychoactive substance responsible for the “high” and can lead to dependence. THC can cause hallucinations, paranoid thoughts and agitation. THC is also associated with impairment of cognition and thinking both in the short term and the long term. THC is a partial agonist at the CB1 receptor⁴. CB1 receptors are found across the brain with high concentrations in the neocortex, basal ganglia and hippocampus⁵. CBD is not thought to be associated with dependence or psychosis and has a mildly sedating effect. CBD lacks significant affinity for the CB1 receptor but it is able to displace THC at low concentrations⁶.

Cannabis with THC content greater than  9% is generally considered “high-potency” cannabis. The international and European trend shows that THC content in both herbal cannabis and resin is increasing⁷,⁸. The THC level of cannabis seized in Ireland is not routinely measured but is expected to be in line with European trends. In 2010 samples of cannabis in Ireland were tested and the THC content ranged from 1 – 16%⁹. Evidence from the US indicates that potency of cannabis products has increased following legalisation¹⁰,¹¹.

The adverse psychoactive effects of cannabis are attributed to the THC component. Studies show that the higher the THC content the greater the risk of psychosis, agitation and anxiety developing³.

For the majority of users, the effects of cannabis intoxication are acute and transient. Many users report pleasurable effects including mild euphoria and a feeling of relaxation.  Undesirable experiences (particularly with high potency cannabis) include panic attacks, dysphoria, suspiciousness and paranoia, perceptual distortions, hallucinations, cognitive impairment and psychomotor impairment³,¹².

The cognitive and psychomotor effects of cannabis account for impairment of driving and operating machinery¹³. The combination of alcohol and cannabis intoxication has a synergistic effect on driving impairment which exceeds the risk of using either exclusively¹⁴.  The Gardaí began roadside testing for cannabis and other substances in 2016. In 2018 cannabis was implicated in 1,205 cases of road traffic offences according to the Medical Bureau of Road Safety. A recent study suggests that chronic cannabis use can impair users’ driving even after a 12-hour abstinence period¹⁵.

Yes, cannabis is addictive and can lead to Cannabis Use Disorder. Stopping cannabis consumption after a period of use can result in significant withdrawal effects (irritability, anxiety, decreased appetite, restlessness, and sleep disturbance)¹⁶.

The 2014/15 Drug Prevalence Survey conducted by the National Advisory Committee on Drugs and Alcohol¹ found that 1 in 5 people who use cannabis report symptoms consistent with cannabis dependence. This rate of cannabis use disorder is consistent with international findings and can increase to 1 in 3 in the case of adolescent users who use large amounts of cannabis¹⁷. A cannabis use disorder is now the most common presenting problem for people seeking addiction treatment under the age of 25 years, even more common than alcohol use disorder¹⁸. From 2006-2016 there was a two-fold increase in adolescents entering the addiction service for treatment of a cannabis use disorder¹⁸. The risk of dependence increases with increased frequency of use and higher potency cannabis. A review based on US data showed early use is a predictor of dependence, people who begin using cannabis before age 18 are four to seven times more likely to develop a cannabis use disorder¹⁹.

The gateway hypothesis proposes that cannabis use leads to use of other drugs such as cocaine, amphetamine and heroin. Although scientific evidence is mixed on this question, a recent large study of predictors of later opioid use disorder in the US has shown that early cannabis use (before age 18) was the dominant predictor²⁰. An Australian twin study showed that twins who started using cannabis by age 17 were 2-5 times more likely than their non-cannabis using co-twin to go on to use other substances and to become dependent on drugs or alcohol²¹.

Yes. Cannabis use can precipitate new mental illness and exacerbate pre-existing mental illness. A study¹⁸ using the National Psychiatric In-Patient Reporting System (NPIRS) data found that cannabis- related admissions had increased by 140% between 2011 and 2017 for people aged 15-34.


Cannabis users are at a 3-4 fold increased risk of development of acute psychosis²² with evidence that this association is increased to 5-6 fold with early use of high potency cannabis²³.  People with cannabis-induced psychosis are at high risk of progression to a chronic psychotic disorder such as schizophrenia. It has been shown that 1 in 5 people who suffer cannabis-induced psychosis will progress to a schizophrenia diagnosis within 3-4 years²⁴.

Mood Disorders

Early-onset use of cannabis is also associated with an increased risk of development of major depressive disorder²⁵,²⁶. Cannabis use disorder has been associated with a greater risk of Bipolar affective disorder onset²⁷ and reduced length of time between relapses.

Anxiety Disorders

Young cannabis users are at higher risk of anxiety disorders particularly those who use high potency cannabis²⁸.

Suicidal behaviours

Chronic cannabis users are more likely to report thoughts of suicide than non-users. The National Self-Harm Registry Ireland Annual Report 2018 states that cannabis was the most common illicit drug used among men aged 15-24 with self-harm presentations – present in 8% of overdose acts²⁹. A recent systematic review found that the risk for suicide attempts in young cannabis users was more than 3 times higher than in young people who did not use cannabis²⁶.

The use of high potency (high THC) cannabis regularly and starting to use cannabis at an early age are the strongest risk factors for developing a psychotic disorder among cannabis users³⁰. Other important risk factors are a family history of psychosis and individual genetic vulnerabilities. THC has been shown to induce psychosis in healthy people with no history of mental illness¹². The Report from the National Academies of Science, Engineering and Medicine (2017) has stated that cannabis use is associated with psychosis:  higher the dose, the higher the risk²⁷.

The highest risk is for users of high potency cannabis on a regular basis. However, studies have shown that even a small amount of cannabis exposure in early adolescence may be related to structural brain changes and mental illness³¹.

Cannabis use has effects on brain structure and development³²,³³. The adolescent brain seems to be most at risk from neurodevelopment and structural changes³⁰. Cannabis has an effect on synaptic pruning and white matter brain development and users with a “still developing brain” are at most risk³⁰,³⁴. While chronic and high frequency use of cannabis is associated with structural brain differences a recent review has shown that even low exposure to cannabis during adolescence may result in changes in grey matter volume in the brain³¹. Larger studies and further replication are required to investigate this relationship.

Cannabis use during pregnancy is associated with low birth weight and disruption of the endocannabinoid system which may lead to neurodevelopmental problems³⁵ including autism spectrum disorder³⁶. For these reasons, cannabis should be avoided in pregnancy.

Cannabis use can adversely influence academic and work performance and is linked to decreases in IQ in those who use cannabis heavily at a young age³⁷ᵃᵇ. A recent systematic review of the evidence reports average decline of approximately 2 IQ points following exposure to cannabis in youth³⁸. Cannabis use decreases memory performance tasks in students³⁹. Multiple studies across different sites have shown early life cannabis use, is strongly associated with poorer educational outcomes, lower income, greater welfare dependence and unemployment and lower relationship and life satisfaction⁴⁰,⁴¹.

Yes, cannabis use is associated with harms for the user, their family and the society they live in. All parental addictions, including cannabis use disorder, are now recognised as constituting an adverse childhood experience (ACE) and children growing up with increased ACEs have poorer health and socioeconomic outcomes⁴²,⁴³. A severe cannabis use disorder can lead to parenting problems, and neglect of children. The HSE and TUSLA have issued a joint advisory document on addressing these hidden harms of substance use disorders which has practical advice on problem drug use within households⁴⁴.

Cannabis use has also been implicated in many road traffic accidents. In the US, the states that legalised recreational cannabis sales had higher traffic fatalities in the year following legislation change⁴⁵. Cannabis use increases the risk of violent behaviour⁴⁶, especially in individuals with psychotic disorders⁴⁷. Cannabis use is also implicated in domestic violence and in cases where children are exposed to violence⁴⁸,⁴⁹. Teenagers and young adults with cannabis use disorders can cause substantial distress to their parents and siblings⁵⁰, and clinical services in Ireland and elsewhere note that child-to-parent violence occurs frequently in these situations⁵¹.

A comprehensive recent review found that cannabis-based products are not effective in the treatment of mental illnesses (e.g. psychosis, depressive disorders, anxiety disorders, post-traumatic stress disorder and Tourette’s syndrome), and were associated with adverse side effects⁵². There is concern that people with mental illnesses may self-medicate with cannabis, or have it unwisely recommended to them, and this may delay both appropriate help-seeking and provision of evidence-based treatments. At time of publication cannabis and cannabis products are not evidence- based treatments for mental illness. Studies are ongoing to investigate whether cannabidiol (CBD) may be used in the treatment of schizophrenia and substance dependence. There are no definitive results as yet.

Cannabis smoke contains similar toxins to those found in tobacco smoke (e.g. carbon monoxide, aldehydes, acrolein, phenols and carcinogenic polycyclic aromatic hydrocarbons)⁵³. In Irish general hospitals, it has been noted that there was a three-fold increase in the number of admissions of young adults with a cannabis related diagnosis between 2005 and 2017¹⁸. Cannabis use is associated with physical harms including: cannabis hyperemesis syndrome⁵⁴, exacerbation of respiratory illnesses including bronchitis⁵⁵,⁵⁶, cardiovascular illness including stroke and cardiac arrhythmias and certain types of cancer⁵⁷,⁵⁸.

A scoping review of 72 systematic reviews concerning the benefits and harms of medical cannabis found mild harms were frequently reported. The authors state the harms of cannabis-based medicines may outweigh the benefits⁶⁰.

In common with other substances, including alcohol, many people experience the short-term effects as pleasurable. Survey data both nationally and internationally would suggest the perception of the harms of cannabis have diminished over recent years especially among adolescents¹⁸.  Current research is on-going to assess and understand this trend. Possible factors include favourable media coverage of cannabis use, misunderstanding and misrepresentation of the early evidence on cannabis-based products as therapeutic agents, social media misinformation and effects of commercial cannabis marketing⁵⁹.

  1. National Advisory Committee on Drugs and Alcohol. Prevalence of Drug Use and Gambling in Ireland and Drug Use in Northern Ireland. (2016).
  2. ESPAD Group (2020), ESPAD Report 2019: Results from the European School Survey Project on Alcohol and Other Drugs, EMCDDA Joint Publications, Publications Office of the European Union, Luxembourg
  3. Murray, R. M., Quigley, H., Quattrone, D., Englund, A. & Di Forti, M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 15, 195–204 (2016).
  4. Pertwee, R. G. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199–215 (2008).
  5. Howlett, A. C. et al. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13, 420–423 (1990).
  6. Bisogno, T. et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845–852 (2001).
  7. European Monitoring Centre for Drugs and Drug Addiction (2019), European Drug Report 2019: Trends and Developments, Publications Office of the European Union, Luxembourg. doi:10.1097/JSM.0b013e31802b4fda
  8. Freeman, T. P. et al. Increasing potency and price of cannabis in Europe, 2006–16. Addiction 114, 1015–1023 (2019).
  9. Arnold, C. The Potency of THC in Cannabis Products. National Advisory Committee on Drugs Working Paper Series No. 1 1, (2011).
  10. Smart, R., Caulkins, J. P., Kilmer, B., Davenport, S. & Midgette, G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 112, 2167–2177 (2017).
  11. Hall, W. & Lynskey, M. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. World Psychiatry 19, 179–186 (2020).
  12. D’Souza, D. C. et al. The psychotomimetic effects of intravenous delta-9- tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29, 1558–1572 (2004).
  13. Hartman, R. L. & Huestis, M. A. Cannabis effects on driving skills. Clin. Chem. 59, 478–492 (2013).
  14. Dubois, S., Mullen, N., Weaver, B. & Bédard, M. The combined effects of alcohol and cannabis on driving: Impact on crash risk. Forensic Sci. Int. 248, 94–100 (2015).
  15. Dahlgren, M. K. et al. Recreational cannabis use impairs driving performance in the absence of acute intoxication. Drug Alcohol Depend. 107771 (2020). doi:10.1016/j.drugalcdep.2019.107771
  16. Budney, A. J. & Hughes, J. R. The cannabis withdrawal syndrome. Curr. Opin. Psychiatry 19, 233–238 (2006).
  17. Leung, J., Chan, G. C. K., Hides, L. & Hall, W. D. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addict. Behav. 109, 106479 (2020).
  18. Smyth, B. P., O’Farrell, A. & Daly, A. Cannabis use and Associated Health Problems – What’s the Harm? Ir. Med. J. 112, 1000 (2019).
  19. Winters, K. C. & Lee, C.-Y. S. Likelihood of developing an alcohol and cannabis use disorder during youth: Association with recent use and age. Drug Alcohol Depend. 92, 239–247 (2008).
  20. Wadekar, A. S. Understanding Opioid Use Disorder (OUD) using tree-based classifiers. Drug Alcohol Depend. 208, 107839 (2020).
  21. Lynskey, M. T. et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. J. Am. Med. Assoc. 289, 427–433 (2003).
  22. Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M. & Vassos, E. Meta-Analysis of the association between the level of cannabis use and risk of psychosis. Schizophr. Bull. 42, 1262–1269 (2016).
  23. Di Forti, M. et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet Psychiatry 2, 233–238 (2015).
  24. Kendler, K. S., Ohlsson, H., Sundquist, J. & Sundquist, K. Prediction of onset of substance- induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. Am. J. Psychiatry 176, 711–719 (2019).
  25. Schoeler, T. et al. Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: Findings from 40 years of follow-up. Psychol. Med. 48, 2169– 2176 (2018).
  26. Gobbi, G. et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry 1–9 (2019). doi:10.1001/jamapsychiatry.2018.4500
  27. Cougle, J. R., Hakes, J. K., Macatee, R. J., Chavarria, J. & Zvolensky, M. J. Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J. Psychiatr. Res. 66–67, 135–141 (2015).
  28. Hines, L. A. et al. Association of High-Potency Cannabis Use with Mental Health and Substance Use in Adolescence. JAMA Psychiatry 1–8 (2020). doi:10.1001/jamapsychiatry.2020.1035
  29. Griffin, E, McTernan N, Wrigley, C, Nicholson, S, Arensman, E, Williamson, E, Corcoran, P. National Self-Harm Registry Ireland Annual Report 2018. Cork: National Suicide Research Foundation (2019).
  30. Lubman, D. I., Cheetham, A. & Yücel, M. Cannabis and adolescent brain development. Pharmacol. Ther. 148, 1–16 (2015).
  31. Orr, C. et al. Grey matter volume differences associated with extremely low levels of cannabis use in adolescence. J. Neurosci. 39, 1817–1827 (2019).
  32. Battistella, G. et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 39, 2041–2048 (2014).
  33. Lorenzetti, V., Hoch, E. & Hall, W. Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. Eur. Neuropsychopharmacol. 1–12 (2020). doi:10.1016/j.euroneuro.2020.03.012
  34. van der Steur, S. J., Batalla, A. & Bossong, M. G. Factors moderating the association between cannabis use and psychosis risk: A systematic review. Brain Sci. 10, (2020).
  35. Ryan, S. A. et al. Marijuana use during pregnancy and breastfeeding: Implications for neonatal and childhood outcomes. Pediatrics 142, (2018).
  36. Corsi, D. J. et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat. Med. In Press, (2020).
  37. (a)Gonzalez, R. & Swanson, J. M. Long-term effects of adolescent-onset and persistent use of cannabis. Proc. Natl. Acad. Sci. U. S. A. 109, 15970–15971 (2012).
    (b)Meier, M. H. et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl. Acad. Sci. U. S. A. 109, (2012).
  38. Power E, Sabherwal S, Healy C, O’ Neill A, Cotter D, Cannon M. Intelligence quotient decline following frequent or dependent cannabis use in youth: A systematic review and meta- analysis of longitudinal studies. Psychol Med. 2021;
  39. Schuster, R. M. et al. One Month of Cannabis Abstinence in Adolescents and Young Adults Is Associated With Improved Memory. J. Clin. Psychiatry 79, (2018).
  40. Fergusson, D. M., Boden, J. M. & Horwood, L. J. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Soc. Psychiatry Psychiatr. Epidemiol. 50, 1317–1326 (2015).
  41. Horwood, L. J. et al. Cannabis use and educational achievement: Findings from three Australasian cohort studies. Drug Alcohol Depend. 110, 247–253 (2010).
  42. Hughes, K. et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. Lancet Public Heal. 2, e356–e366 (2017).
  43. Madras, B. K. et al. Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse. JAMA Netw. open 2, e1916015 (2019).
  44. HSE/Tusla. Hidden Harm Practice Guide – Seeing through Hidden Harm to brighter futures. (2019).
  45. Lane, T. J. & Hall, W. Traffic fatalities within US states that have legalized recreational cannabis sales and their neighbours. Addiction 114, 847–856 (2019).
  46. Dellazizzo, L. et al. Association Between the Use of Cannabis and Physical Violence in Youths: A Meta-Analytical Investigation. Am. J. Psychiatry 177, 619–626 (2020).
  47. Pickard, H. & Fazel, S. Substance abuse as a risk factor for violence in mental illness: Some implications for forensic psychiatric practice and clinical ethics. Curr. Opin. Psychiatry 26, 349–354 (2013).
  48. Shorey, R. C. et al. Marijuana use is associated with intimate partner violence perpetration among men arrested for domestic violence. Transl. Issues Psychol. Sci. 4, 108–118 (2018).
  49. Reingle, J. M., Staras, S. A. S., Jennings, W. G., Branchini, J. & Maldonado-Molina, M. M. The Relationship Between Marijuana Use and Intimate Partner Violence in a Nationally Representative, Longitudinal Sample. J. Interpers. Violence 27, 1562–1578 (2012).
  50. Groenewald, C. & Bhana, A. Mothers’ experiences of coping with adolescent substance abuse: a phenomenological inquiry. Contemp. Nurse 53, 421–435 (2017).
  51. Groenewald, C. & Bhana, A. “It was Bad to See My [Child] Doing this”: Mothers’ Experiences of Living with Adolescents with Substance Abuse Problems. Int. J. Ment. Health Addict. 14, 646–661 (2016).
  52. Black, N. et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The lancet. Psychiatry 0366, 1–16 (2019).
  53. Moir, D. et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem. Res. Toxicol. 21, 494–502 (2008).
  54. Sorensen, C. J., DeSanto, K., Borgelt, L., Phillips, K. T. & Monte, A. A. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review. J. Med. Toxicol. 13, 71–87 (2017).
  55. Tashkin, D. P. Effects of marijuana smoking on the lung. Ann. Am. Thorac. Soc. 10, 239–247 (2013).
  56. Douglas, I. S. et al. Implications of marijuana decriminalization on the practice of pulmonary, critical care, and sleep medicine: A report of the American thoracic society marijuana workgroup. Ann. Am. Thorac. Soc. 12, 1700–1710 (2015).
  57. Mehra, R., Moore, B. A., Crothers, K., Tetrault, J. & Fiellin, D. A. The association between marijuana smoking and lung cancer: A systematic review. Arch. Intern. Med. 166, 1359–1367 (2006).
  58. Huang, Y.-H. J. et al. An Epidemiologic Review of Marijuana and Cancer: An Update. Cancer Epidemiol. Biomarkers Prev. 24, 15–31 (2015).
  59. Abraham, A. et al. Media Content Analysis of Marijuana’s Health Effects in News Coverage. J. Gen. Intern. Med. 33, 1438–1440 (2018).
  60. Pratt M, Stevens A, Thuku M, Butler C, Skidmore B, Wieland LS, et al. Benefits and harms of medical cannabis: A scoping review of systematic reviews. Syst Rev. 2019;8(1):1–35.